A practical reference on peptide mapping: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-30. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
=== Other uses === The demand for selenium by the electronics industry is declining. Its photovoltaic and photoconductive properties are still useful in photocopying, photocells, light meters and solar cells. Its use as a photoconductor in plain-paper copiers once was a leading application, but in the 1980s, the photoconductor application declined (although it was still a large end-use) as more and more copiers switched to organic photoconductors. Zinc selenide was the first material for blue LEDs, but gallium nitride dominates that market. Cadmium selenide can be used to make quantum dots. Sheets of amorphous selenium convert X-ray images to patterns of charge in xeroradiography and in solid-state, flat-panel X-ray cameras. Ionized selenium (Se+24, where 24 of the outer D, S and P orbitals are stripped away due to high input energies) is one of the active mediums used in X-ray lasers. 75Se is used as a gamma source in industrial radiography. Selenium catalyzes some chemical reactions, but it is not widely used because of issues with toxicity. In X-ray crystallography, incorporation of one or more selenium atoms in place of sulfur helps with multiple-wavelength anomalous dispersion and single wavelength anomalous dispersion phasing. Selenium is used in the toning of photographic prints, and it is sold as a toner by numerous photographic manufacturers. Selenium intensifies and extends the tonal range of black-and-white photographic images and improves the permanence of prints.
=== Disease === Pathological factors can also influence drug metabolism, including liver, kidney, or heart disease. In silico modelling and simulation methods allow drug metabolism to be predicted in virtual patient populations prior to performing clinical studies in human subjects. This can be used to identify individuals most at risk from adverse reaction.
== Spectrum == The mass spectrum of the secondary ions emitted from the bombarded surface during SSIMS provides direct information of not only the chemical composition but also of the chemical structure of the bombarded area. This is because the mass spectrum includes cluster ions as well as elemental ions. These cluster ions reflect the surface chemistry in a detailed way. The figure shows the mass spectrum obtained from a SSIMS analysis of polytetrafluoroethylene (PTFE). The positive ion spectrum shows positive atomic ions (i.e. C+) and molecular ions (i.e. CF+, CF3+, C3F3+) of the target. The negative ion spectrum shows negative atomic ions (i.e. F−) and molecular ions (i.e. F2−, CF3−, C3F3−).
== Adverse effects == Adverse effects are relatively rare when used to treat the joints. When used in ophthalmological procedures, sodium hyaluronate may cause postoperative inflammation, corneal edema or decompensation, and short-term increases in intraocular pressure.
=== Chemical === Copernicium is the tenth and last member of the 6d series and is the heaviest group 12 element in the periodic table, below zinc, cadmium and mercury. It is predicted to differ significantly from the lighter group 12 elements. The valence s-subshells of the group 12 elements and period 7 elements are expected to be relativistically contracted most strongly at copernicium. This and the closed-shell configuration of copernicium result in it probably being a very noble metal. A standard reduction potential of +2.1 V is predicted for the Cn2+/Cn couple. Copernicium's predicted first ionization energy of 1155 kJ/mol almost matches that of the noble gas xenon at 1170.4 kJ/mol. Copernicium's metallic bonds should also be very weak, possibly making it extremely volatile like the noble gases, and potentially making it gaseous at room temperature. However, it should be able to form metal–metal bonds with copper, palladium, platinum, silver, and gold; these bonds are predicted to be only about 15–20 kJ/mol weaker than the analogous bonds with mercury. In opposition to the earlier suggestion, ab initio calculations at the high level of accuracy predicted that the chemistry of singly-valent copernicium resembles that of mercury rather than that of the noble gases. The latter result can be explained by the huge spin–orbit interaction which significantly lowers the energy of the vacant 7p1/2 state of copernicium. Once copernicium is ionized, its chemistry may present several differences from those of zinc, cadmium, and mercury.
Sources: en.wikipedia.org
==== Canada ==== Taco Bell has been present in Canada since 1979, with the first store opening in Windsor, Ontario. There are currently Taco Bell locations in 8 of the 10 Canadian provinces: British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick and Nova Scotia, Newfoundland and Labrador. Taco Bell had operated in the province of Quebec for close to 15 years, however announced its withdrawal on January 6, 2022. For some time it was possible to order draft beer with one's order. Taco Bell offers free soda refills in its stores. On March 31, 2011, Priszm, who was the largest franchisee for Taco Bell locations in Canada, went into bankruptcy protection in Ontario and British Columbia. On May 6, 2011, Priszm Income Fund was delisted from the Toronto Stock Exchange for failure to meet the continued listing requirements. Since then, some Taco Bell restaurants have been closed down including those in Guelph, Hamilton, and Cambridge, Ontario, among others.
The introduction of Di(2-propylheptyl) phthalate (DPHP) was driven by increasing regulatory scrutiny and health concerns associated with traditional plasticizers. DPHP was developed to meet the demand for plasticizers with improved safety profiles, particularly in applications involving human contact. As a result of its production through the esterification of phthalic anhydride with 2-propylheptanol, it results in a compound with low volatility and high thermal stability, making it suitable for various applications, including automotive interiors, wire and cable insulation, and flooring materials. The compound gained regulatory attention in the European Union, where it was included in the Community Rolling Action Plan (CoRAP) under the REACH regulation in 2014. This inclusion was due to concerns about its widespread use, potential endocrine-disrupting properties, and exposure risks to sensitive populations. Germany was tasked with evaluating DPHP's health and environmental impacts, with the assessment process beginning in 2020. Research into DPHP's metabolism and exposure markers has been conducted to better understand its behavior in biological systems. A 2019 study utilized ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) in a rat model to identify potential biomarkers for DPHP exposure, aiding in the assessment of human exposure levels.
=== Iodine-124 === Iodine-124 is a proton-rich isotope of iodine with a half-life of 4.1760 days, decaying to 124Te by 77.3% electron capture and 22.7% positron emission. Iodine-124 can be made by numerous nuclear reactions in a cyclotron. The most common starting material used is 124Te. Iodine-124 as the iodide salt can be used to directly image the thyroid using positron emission tomography (PET). Iodine-124 can also be used as a PET radiotracer with a usefully longer half-life compared with fluorine-18. In this use, the nuclide is chemically bonded to a pharmaceutical to form a positron-emitting radiopharmaceutical, and injected into the body, where again it is imaged by PET scan.
=== Skin === Estrogens cause the accumulation of subcutaneous fat and an increased epidermal thickness, softening the skin. Some skin conditions, including melasma, are found in trans women at the same rate at cisgender women. Body odor and sweat patterns are changed by feminizing hormone therapy, while sebaceous gland activity lessens, reducing oil production on the skin and scalp. Consequently, the skin becomes less prone to acne. It also becomes drier, and lotions or oils may be necessary.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.